Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. 2013 July 1; 123(7): 2873–2892.
Published online 2013 June 17. doi:  10.1172/JCI67428
PMCID: PMC3696556

CD4+ follicular helper T cell infiltration predicts breast cancer survival


CD4+ T cells are critical regulators of immune responses, but their functional role in human breast cancer is relatively unknown. The goal of this study was to produce an image of CD4+ T cells infiltrating breast tumors using limited ex vivo manipulation to better understand the in vivo differences associated with patient prognosis. We performed comprehensive molecular profiling of infiltrating CD4+ T cells isolated from untreated invasive primary tumors and found that the infiltrating T cell subpopulations included follicular helper T (Tfh) cells, which have not previously been found in solid tumors, as well as Th1, Th2, and Th17 effector memory cells and Tregs. T cell signaling pathway alterations included a mixture of activation and suppression characterized by restricted cytokine/chemokine production, which inversely paralleled lymphoid infiltration levels and could be reproduced in activated donor CD4+ T cells treated with primary tumor supernatant. A comparison of extensively versus minimally infiltrated tumors showed that CXCL13-producing CD4+ Tfh cells distinguish extensive immune infiltrates, principally located in tertiary lymphoid structure germinal centers. An 8-gene Tfh signature, signifying organized antitumor immunity, robustly predicted survival or preoperative response to chemotherapy. Our identification of CD4+ Tfh cells in breast cancer suggests that they are an important immune element whose presence in the tumor is a prognostic factor.


Breast cancer (BC) is a complex and heterogeneous disease whose classification has been significantly improved in recent years through the development of gene expression signatures that currently identify 4 clinically distinct neoplastic diseases: luminal A and B, ER, and HER2+ (1, 2). However, significant disparity in clinical outcome still remains within each of these disease entities, leading investigators to continue searching for more refinement. Initially, prognostic molecular signatures focused on the malignant cell, improving BC taxonomy via the assessment of genes regulating the cell cycle and proliferation (3, 4). More recently, attention has turned to the various nonneoplastic cells present in tumors, including stromal cells and infiltrating leukocytes, whose interactions with tumor cells can have a major influence on an individual patient’s long-term outcome. Clinical studies using prognostic and predictive signatures have shown that the strength of the immune signal emanating from whole tumor gene expression profiles reflects the level of immune infiltration. A high immune signal has been linked with improved patient outcome in a variety of cancers (5), including subtypes of BC, with the strongest correlation for the latter observed in the ER and HER2+ subtypes (613). Although there is not a consensus on the individual immune cell subset(s) that consistently mediates this effect, an important link between preexisting antitumor immune responses and long-term positive clinical outcome has been established (14).

Traditionally, CD8+ cytotoxic T cells have been considered as the key component of effective antitumor immunity, and breast tumors with higher levels of infiltrating CD8+ T cells have been associated with better patient survival (15, 16). However, studies have also shown that CD8+ T cells frequently fail to fully function in vivo if there is a lack of adequate CD4+ T cell help (17, 18). As central players in the immune system, CD4+ T cells perform critical roles in recruiting, activating, and regulating many facets of the adaptive immune response, with their helper functions for B cell– and CD8+ cytotoxic T cell–mediated responses well documented. CD4+ T cells also influence innate immunity by helping to shape the character and magnitude of the inflammatory response.

One common observation from functional studies is that many of the infiltrating leukocyte subpopulations do not expand or function normally within the tumor microenvironment. The current consensus is that IFN-γ–producing CD4+ Th1 and CD8+ T cells, along with mature DCs, NK cells, M1 macrophages, and type 1 NKT cells can generate effective although frequently attenuated antitumor responses, while CD4+ Th2 cells and type 2 NKT cells in cooperation with CD4+ Tregs (regulatory), myeloid-derived suppressor cells, immature DCs, or M2 macrophages suppress antitumor immunity and can also promote tumor progression (1921). However, this generalization comes with the caveat that variation exists among tumor types, with the so-called protumorigenic cells, such as CD4+ Th17, also shown to produce effective antitumor responses (20, 22, 23). Emerging from these studies is recognition that the various CD4+ Th subsets have important functions in both protumor and antitumor immunity, with IFN-γ–producing Th1 cells currently most frequently associated with superior antitumor immune responses. In BC, the majority of previous investigations focusing on CD4+ T cells have examined the suppressive activities of Tregs in dampening immune functions (24).

This study was undertaken to characterize the CD4+ T cell subpopulations infiltrating human breast tumors in a direct ex vivo analysis of fresh tumor tissue without enzymatic digestion or short-term in vitro expansion. We profiled gene expression in purified CD4+ T cells from the primary tumors (referred to herein as TIL), axillary LN, and peripheral blood (PB) to produce global images of these cells in their native state. An important finding from our work is that extensively infiltrated tumors are less immunosuppressive and have a higher frequency of organized LN-like structures associated with detectable CXCL13-producing CD4+ follicular helper T (Tfh) cells. Tertiary lymphoid structures (TLS) have been previously identified in lung and colorectal cancers, and their presence has been linked with positive patient prognosis (2527). In this study we show that Tfh cells are an important constituent of TLS in breast tumors. Animal models have demonstrated that Tfh cells in LNs are highly activated and participate in various steps leading to germinal center (GC) development and differentiation of memory B and antibody-secreting plasma cells (28). The data presented here suggest that CXCL13-producing Tfh TIL may play an important role in immune cell recruitment to the tumor microenvironment and influence TLS formation, thereby helping to create a haven in the tumor mass in which effective and durable antitumor immune responses can be generated.


The immune infiltrate in BC.

Freshly resected invasive breast tumor tissue from systemically untreated patients (a graphical overview for navigating the experimental data is provided in Supplemental Table 1A; supplemental material available online with this article; doi:10.1172/JCI67428DS1; clinicopathological characteristics for the patient discovery set [n = 10] in Supplemental Table 1B and patient confirmation set [n = 60] in Supplemental Table 1C) was rapidly mechanically dissociated into a single cell homogenate using the GentleMACS system for immediate ex vivo analysis following CD4+ T cell isolation. The distribution of infiltrating CD45+ cells (Supplemental Figure 1) included a majority of T cells (±75%; range = 60%–90%) together with <20% B cells, <10% monocytes, <5% NK cells, or NKT cells, similar to a recently published study (29). Among the CD3+ T cells, the CD4+ subset was consistently the principal component (Figure (Figure1A;1A; mean = 53% in 35 tumors), outnumbering CD8+ T cells and present both at a higher frequency and ratio than in ipsilateral nonadjacent normal breast tissue (mean = 38% in 31 samples).

Figure 1
Characteristics of CD4+ T cells infiltrating breast tumors.

Features of the CD4+ T cell infiltrate.

Global gene expression profiles of the TIL were compared with CD4+ T cells from patient’s axillary LN and PB (P-PB) and PB from healthy donors (D-PB) (Supplemental Table 1B). Bootstrap analysis revealed stable groupings by tissue type, with patient and donor blood segregating together (Figure (Figure1B).1B). This observation could be partially due to differences in the ratio of naive (CD45RA+) to memory (CD45RO+) CD4+ T cells, with generally about 50% CD45RO+ in PB, >50% in LN, and >95% in TIL (expression of the 58 Th surface markers investigated was also examined on naive and memory donor CD3+CD4+ T cells as a control; Supplemental Figure 2). The gene expression profiles were analyzed in a variety of comparisons, including TIL compared with LN or P-PB, P-PB compared with D-PB, and ER+ compared with ER tumors (Supplemental Table 2). The extent of the CD4+ T cell infiltrate (IHC; Supplemental Table 1B) revealed that 2 ER+ and 2 ER tumors were extensively infiltrated while 3 ER+ and 3 ER tumors were minimally infiltrated, with these groups also compared. Our analyses initially (a) concluded that the CD4+ T cell profiles were remarkably similar between P-PB and D-PB (Supplemental Table 2E), with the autologous cells constituting a good internal control; (b) found surprisingly few gene changes between ER+ and ER tumors (Supplemental Table 2F); and (c) detected important differences in immune response genes between extensively and minimally infiltrated tumors (Supplemental Table 2G), which will be detailed throughout this article (extensively infiltrated is defined as overall >5% intratumoral and >10% stromal lymphocytes in multiple sections of the resected invasive tumor; criteria detailed in Supplemental Table 1C).

Molecular images of the CD4+ Th subsets present in the TIL were produced by comparing our patient data with public Th gene expression data sets (refs. 3032; reanalyzed applying our small group criteria [ref. 33] which are detailed in the Supplemental Methods). Our innovative use of these public data sets allowed us to detect the presence of each CD4+ T cell subpopulation in the TIL and extend the individual Th subset profiles beyond conventional markers with relative specificity. A direct comparison of patient CD4+ T cell data with the public Th gene lists produced distinct gene sets (Figure (Figure1,1, C–H; Figure Figure2,2, A–C; and Supplemental Table 3) showing that (a) D-PB and P-PB are relatively similar across all Th subsets, with a slight increase in effector memory cell markers in P-PB; (b) LN profiles are transitional between P-PB and TIL, with upregulation of the Tfh genes CD200, CXCL13, and ICOS and the Th1 genes CD38 (34), CXCL9, IFNG, and IL2, which are notably among the limited number of gene alterations detected (Figure (Figure3);3); (c) the TIL profile is enriched in all major Th subpopulations (Th1, Th2, Tfh, Treg, and Th17); (d) the TIL are activated CD25+ cells; and (e) the TIL have a memory phenotype closer to that of effector than that of central memory cells. Expression levels of conventional Th markers (Supplemental Table 3K) reiterated that all Th subpopulations were present in the TIL but did not provide definite information on their relative distribution. Alternatively, the comparison of TIL from extensively versus minimally infiltrated tumors revealed a distinct skew to Tfh (CD200, CXCL13, ICOS, and PDCD1 [known as PD-1]) and Th1 (CD38, CXCL9, CXCL10, CXCL11, IFNG, and TBX21 [also known as T-bet]) gene expression in the extensively infiltrated tumors (Figure (Figure3).3). The Treg marker FOXP3 was also increased in extensively versus minimally infiltrated tumors (Figure (Figure3),3), but the Treg produced ligand TGFB2 was decreased in this comparison (both were significantly increased in TIL compared with D-PB). This suggests that the observed increase in FOXP3 expression may be related to its transient expression by activated Th cells rather than a greater presence of Tregs in the extensively infiltrated tumors.

Figure 2
Characteristics of CD4+ T cells infiltrating breast tumors.
Figure 3
Conventional Th subset marker expression in TIL.

Flow cytometric analysis of CD4+ TIL from additional patients with BC compared with CD4+ T cells from healthy donor blood (Supplemental Table 1C) largely validated these data and provided more quantitative information, demonstrating that the CD4+ TIL are antigen-experienced effector memory cells (CD45RO+), characterized either wholly or in a subpopulation of cells as TCR/CD3lo CD6lo CD7lo CD11b+ CD18+ CD24+ CD25+ CD26+ CD27lo CD28lo CD35 CD38+ CD43lo CD44+ CD49D+ CD54hi CD55lo CD57lo CD58hi CD59+ CD62Llo CD69+ CD71+ CD73+ CD80+ CD86+ CD109+ CD146+ CD166+ CD200+ CCR4+ CCR5+ CCR6lo CCR7lo CX3CR1lo CXCR3+ CXCR4+ CXCR5+ 4-1BB+ BTLA+ CRTH2+ CTLA4+ FAShi GITR+ HLA-DR+ ICOS+ IL1R1+ IL2RB+ IL6STlo IL7R+ IL12RB2+ IL17RB+ IL17RD+ OX40+ OX40L+ PD-1+ TGFBR2+ TGFBR3+ (Supplemental Figure 2). The heterogeneity observed in some activation-induced markers (e.g., CD25, CD71, HLA-DR) suggests that not all of the cells are activated. Upregulation of conventional Th surface markers on CD4+ TIL subpopulations was detected (Supplemental Figure 2) and included (a) the Tfh-associated BTLA, CD200hi, ICOS, and PD-1hi; (b) the Th1-associated CD38hi, CCR5, CD54, and IL12RB2; (c) the Th2-associated CCR4; (d) the Th17-associated IL1R1; and (e) the Treg-associated CD25hi and GITR. Histogram or dot plot thumbnails are shown for Th surface marker genes present in the Figure Figure1,1, C–H, and Figure Figure2,2, A–C, heat maps (Figure (Figure2D;2D; full histograms or dot plots in Supplemental Figure 2). Interestingly, among differentially expressed surface markers (Figure (Figure2D,2D, underlined in blue), CD38, CD200, ICOS, and PD-1 expression was higher on CD4+ TIL from extensively infiltrated tumors, which was confirmed at the mRNA level (Figure (Figure33).

Many of the gene and surface markers expressed on some or all of the TIL reflect an activated state; however, only low levels of Th-derived cytokines/chemokines had statistically significant increases in the TIL versus P-PB comparison (Figure (Figure3).3). Analyses using more sensitive quantitative PCR with reverse transcription (qRT-PCR) confirmed these gene expression increases and expanded the set of expressed Th-derived factors (Tfh [CXCL13 and IL21], Th1 [CXCL9, CXCL10, CXCL11, GZMA, GZMB, IFNG, and IL2], Th2 [IL13], Th17 [CCL20, IL17A, IL17F, IL21, and IL22], and Tregs [IL10, TGFB, and XCL1]), although many were not at stimulation-induced (S-induced) levels (microarray data), with reduced expression more pronounced in minimal relative to extensively infiltrated tumors. These data indicate that while all Th subsets are infiltrating BC, the full complement of Th cytokines/chemokines is not produced.

Concurrent activation and suppression.

The lack of robust or comprehensive cytokine/chemokine expression by the CD4+ TIL led us to investigate the nature of their activation state. Evaluation of prototypic TCR/CD3 pathway genes identified a substantial number that were downregulated in the TIL compared with their counterparts from LN or P-PB (Figure (Figure4).4). This suppression includes components of the TCR/CD3 complex, molecules involved in signal transduction, costimulatory receptors, transcription factors, and negative regulatory molecules (genes detailed in Supplemental Table 4). Some of these gene changes were confirmed at the mRNA (Supplemental Table 5B) or protein levels (Supplemental Figure 2). TCR/CD3 downregulation on TIL has been described for a wide variety of solid tumors (35), but the depth of this suppression, extending through the signaling pathway and divergent from activation-induced modifications, has not been previously reported. A comparison with gene expression profiles of stimulated donor CD4+CD45RO+ T cells revealed that only approximately 50% were similarly induced or repressed by TCR/CD3 activation (Figure (Figure44 and Supplemental Table 4). The disparity with T cell activation is highlighted by the number of aberrantly expressed coreceptors, which are involved in regulating the TCR/CD3 signal. Interestingly, the NF-κB transcription factor REL and members of the AP-1 family (ATF3, BATF, FOSB/FOSL2, and JUN/JUND were specifically upregulated despite reduced upstream MAPK signaling. REL and some AP-1 transcription factor genes were increased in the LN profiles but to a lesser degree (Supplemental Table 2D). An indication that this overall pattern of TCR/CD3 signaling gene expression may be significant is highlighted by the differences observed in extensively versus minimally infiltrated tumors (Figure (Figure5).5). Extensively infiltrated tumors are characterized by higher expression of the TCR/CD3 subunits and numerous coreceptor genes (including CD38, CD200, ICOS, and PDCD1) as well as many signaling genes (including ZAP70) (Figure (Figure3,3, Supplemental Figure 2, Supplemental Table 4, and Supplemental Table 5B). These data suggest that extensively infiltrated tumors are characterized by lower levels of TCR/CD3 suppression and/or higher levels of T cell activation.

Figure 4
TCR/CD3 pathway gene expression in CD4+ TIL.
Figure 5
TCR/CD3 pathway gene expression in CD4+ TIL.

We next performed a series of in vitro experiments to explore this combination of activation and suppression. CD4+ CD45RO+ (or total CD4+) T cells from D-PB were treated with supernatant (SN) retained from fresh primary tumor homogenates, alone or in conjunction with S. SN downregulated TCR/CD3 expression and inhibited activation-induced surface receptor expression, characterized by CD69, ICOS, CD25, and FAS (Figure (Figure6,6, A and B). SN also reduced expression of CXCR5, the receptor for CXCL13, a chemokine that plays an important role in homing to B cell follicles (36). Alternatively, SN and to a lesser degree SN plus S (SN+S), induced expression of CXCR4, the receptor for CXCL12 whose protumor activities are well documented (37). Gene expression arrays revealed that approximately 75% of the genes commonly altered in the TIL and their SN-treated donor PB counterparts were either similarly upregulated or downregulated (Figure (Figure6C6C and Supplemental Table 6B). Expression profiles of the donor SN-treated cells (versus untreated cells) were compared with the TIL versus P-PB data, clearly demonstrating that the SN effect is appreciably amplified by S, with the SN+S cells (Figure (Figure6D6D and Supplemental Table 6C) more closely resembling the TIL than SN alone (Figure (Figure6,6, C–E). The SN+S gene profiles are also distinct from those of S alone (Figure (Figure6E6E and Supplemental Table 6D) and largely reiterate a mixed pattern of activation and suppression.

Figure 6
Tumor SN suppresses activation of donor CD4+ T cells.

Closer examination of the SN+S effect on TCR/CD3 pathway genes (Figure (Figure6,6, G and H, and Supplemental Table 4) detected (a) significant suppression of various signaling genes that was more pronounced than that in the S donor cells; (b) specific upregulation of REL and AP-1/ATF family transcription factors similar to that in the TIL; (c) more potent suppression of a subset of costimulatory receptor genes compared with that in the TIL or S donor cells; and (d) a pattern of negative regulatory gene expression that was similar between the SN+S and S donor cells. Additionally, the SN+S treatment suppressed most of the S-induced changes detected in S counterparts, including expression of the majority of detected cytokines/chemokines (Figure (Figure6I6I and Supplemental Table 6E). Among the Th cytokines/chemokines produced in the S donor cells, only the proinflammatory, tumor-promoting factors CCL20, IL8, and TNF were further upregulated by SN+S treatment. IFNG and the IFN-γ–induced chemokines CXCL9, CXCL10, and CXCL11 were the only S-induced factors also expressed in the TIL, with their overt suppression by SN+S potentially reflecting a stronger effect from higher local concentrations in vitro. This interpretation is reinforced by the observed SN-mediated suppression of CXCR3 (the receptor for CXCL9, CXCL10, and CXCL11; ref. 37 and Supplemental Table 6H) in parallel with CXCR4 upregulation in unstimulated or S donor cells (Figure (Figure6A).6A). Overall, these data support the view that the simultaneously activated/suppressed TIL profile is broadly reproduced by SN+S treatment of donor CD4+ T cells, where the suppressive SN effect is amplified by S.

To determine whether these tumor-mediated effects on CD4+ T cells were transient, freshly isolated TIL were split and either extracted immediately or “rested” ex vivo overnight without S. Gene expression profiling shows the rested TIL reverse expression in a sizable number of genes expressed in their freshly isolated counterparts (Figure (Figure6,6, J and K, and Supplemental Table 6F). Notably, the cytokine/chemokine genes, including IFNG and IFN-γ–induced genes, were upregulated in the TIL and returned to baseline 24 hours after removal from the tumor microenvironment. An exception was the B cell chemoattractant CXCL13, for which the high TIL expression levels decreased only by 50% at 24 hours, with the rested TIL from an extensively infiltrated tumor (TIL064) still expressing CXCL13 at substantially higher levels (159-fold increase) compared with memory D-PB control. Reversal of altered TCR/CD3 pathway gene expression in the rested TIL was limited to BTLA and the AP-1 factors ATF3, FOSB, and JUN, suggesting that suppression of TCR/CD3 signaling is not fully relieved at 24 hours. Additionally, these in vitro experiments show that the immunosuppressive quality of individual BCs varies, with the tendency for SN from tumors sustaining an extensive lymphocyte infiltrate to be less immunosuppressive than those minimally infiltrated (Figure (Figure6,6, C–I). A direct comparison of gene expression in TIL from extensively versus minimally infiltrated tumors supports this conclusion by showing that extensively infiltrated tumors have greater similarity to S donor cells and minimally infiltrated tumors have greater similarity to SN+S donor cells (Figure (Figure6F6F and Supplemental Table 6G).

Significance of extensive infiltration.

The consistently divergent pattern of gene expression detected in CD4+ TIL from extensively versus minimally infiltrated tumors led us to examine the specific genes affected. These analyses found that a variety of immune response genes are expressed at elevated levels in TIL from extensively infiltrated BC, with many perhaps reflecting their higher level of activation (Figure (Figure7A7A and Supplemental Table 2G). The most distinctive increase consistently detected in extensively infiltrated tumors was CXCL13, with CD4+ TIL shown to be the principal cellular source (Figure (Figure7,7, B and C). CXCL13 mRNA expression in tumor sections was recently shown to predict survival of patients with BC, particularly in the HER2+ subtype, although the cell source was not identified (38). An earlier study suggested tumor cells were the major CXCL13 producers in BC but their IHC protocol used higher concentrations of a monoclonal antibody that intensely labeled most cells, both in the tumor tissue and the LN control (39). In contrast, our IHC experiments, using lower concentrations of a polyclonal antibody, stained only some GC-located cells in the LN control, the tumor-associated TLS, and the occasional intratumoral lymphocyte (Supplemental Figure 4C), suggesting that CXCL13 production by tumor cells needs to be reexamined.

Figure 7
Genes predominately expressed in CD4+ TIL from extensively and minimally infiltrated tumors.

In secondary lymphoid organs, such as LNs, CXCL13 is expressed by stromal cells and Th cells in GC, with its ectopic expression promoting lymphoid neogenesis (40). A comparison of CXCL13 expression with other cytokines/chemokines in an extensively and a minimally infiltrated tumor (Figure (Figure7C)7C) showed that the majority were expressed by infiltrating leukocytes (CD14+ monocytes, CD4+ T cells, or the remaining mixture of CD45+ cells) but not the EpCAM+ epithelial/tumor cells. In general, antitumor cytokines/chemokines were detected at considerably higher levels in the extensively compared with the minimally infiltrated tumors (except the protumor chemokine CXCL12). CD4+ T cells and CD14+ monocytes produced the proinflammatory cytokine IL-18 and IFN-γ–induced chemokines CXCL9, CXCL10, and CXCL11, while IFNG itself originated principally from the remaining CD45+ cells (presumably CD8+ T cells; Figure Figure88 showing a high correlation among CD8, CD3, and IFNG gene expression in the non-CD4+ cells).

Figure 8
Correlation among the expression of Tfh marker genes, a Th1 immune profile, and the extent of lymphocyte infiltration.

To gain a better understanding of the relationship between differences detected consistently in extensively versus minimally infiltrated tumors and CXCL13 expression levels, we used qRT-PCR data and lymphocyte infiltration intensities from 21 tumors to produce a correlation plot and generate unsupervised hierarchical clustering (Figure (Figure88 and Supplemental Table 5D). This analysis showed that expression of the IFNG, CXCL9, CXCL10, CXCL11, and CXCL13 genes is correlated with CD38, CD58, CD200, ICOS, and PDCD1 gene expression in CD4+ TIL. Furthermore, these genes were also significantly correlated with lymphocyte infiltration and more specifically with CD8+ T cell and B cell marker expression in the non-CD4+ tumor fraction and negatively correlated with the tumor marker EPCAM. Expression of the surface receptor genes characteristic for Tfh cells (CD200 and PDCD1) (41) and Th1/activated T cells (CD38) (42) correlated best with CXCL13 gene expression in the CD4+ TIL. This is supported by flow cytometry experiments that showed that CXCL13 is predominantly expressed by T cells (primarily CD4+) but not B cells, other CD45+ cells, EpCAM+ epithelial/tumor cells, or endothelial/stromal cells (STRO1+, endoglin+, CD10+, or CD271+) (Figure (Figure9A9A and Supplemental Figure 3). Specifically, the principal CXCL13-producing cells were CD200hi PD-1hi (CD38±) Tfh cells (Figure (Figure9B).9B). While CXCL13 expression and that of the Th1 marker, CD38, are correlated, this non-Tfh receptor is not specific for CXCL13-producing cells, providing additional support for the concept that Tfh, and not other Th, cells produce CXCL13. These experiments also demonstrate that infiltrates from extensively infiltrated tumors are distinguished by CD200hi PD-1hi Tfh cells (Figure (Figure9C).9C). Thus, evidence emerged from our analyses that, in the CD4+ fraction, a Tfh profile (CD200hi, PD-1hi, ICOS, and CXCL13) was associated with a Th1 profile (CD38hi, IFNG, and CXCL9) and both were associated with more extensive lymphocyte infiltration.

Figure 9
Tfh TIL are the major producers of CXCL13 protein.

CXCL13-producing CD4+ Tfh cells infiltrating breast tumors signal organized immunity.

In secondary lymphoid organs, T cells and B cells segregate to separate zones based on CCR7 and CXCR5 expression (28). Upon activation, B cells and CD4+ T cells migrate to the T/B interface for critical interactions that ultimately direct high-affinity CXCR5+ Tfh cells and B cells to migrate in response to CXCL13 to the B cell follicle interior. Once there, they initiate formation of the GC, the site in which memory B cells and long-lived plasma cells are generated. Our identification of a Tfh gene expression profile in extensively infiltrated tumors (highlighted by a strong CXCL13 signal) led us to examine BC for lymphoid aggregates and organized TLS containing GC (Figure (Figure10A,10A, Supplemental Figure 4, and Supplemental Table 1C). TLS and GC were detected adjacent to the tumor bed at a higher incidence in extensively compared with minimally infiltrated tumors (Figure (Figure10B10B and Supplemental Table 1D). The intensity and distribution of the major CD45+ TIL subpopulations within the TLS and GC were analyzed using IHC (Figure (Figure10C10C and Supplemental Figure 4). BC TLS organization is similar to that of LNs, containing a CD3+ T cell zone adjacent to a CD20+ B cell follicle with CD23+ follicular DCs (FDCs) and Bcl6+ Tfh and GC B cells (43) exclusive to the GC, in which Ki67+ cells (proliferating B cells) are also concentrated. CD4+ T cells are the principal component of the T cell zone and also have a significant presence in the GC. CD8+ T cells were moderately interspersed with CD4+ T cells in the T cell zone but absent from the GC; however, they were the principal lymphocyte population in the tumor bed and present at levels that parallel the extent of the total CD45+ infiltrate and the number/size of TLS (Supplemental Figure 4). CXCL13 was principally expressed by T cell zone or GC lymphocytes (primarily infiltrating CD4+PD-1hiCD200hi Tfh cells; Figure Figure9,9, A and B) and FDCs, with intratumoral CXCL13+ lymphocytes detected in some extensively infiltrated tumors (Figure (Figure10D).10D). Interestingly, in a very small GC located within a large TLS (Supplemental Figure 4H), we observed CD4+ T cells and CXCL13 protein associated with CD23lo B cells but not CD23hi FDCs, which might signify that CXCL13-producing Tfh cells associate with B cells earlier than FDCs. Specific CXCL13 labeling of tumor cells was not observed with our IHC conditions (n = 15; Figure Figure10,10, C and D, and Supplemental Figure 4), which is consistent with our flow cytometry data (Figure (Figure9A).9A). Furthermore, CXCL13 IHC labeling was correlated with the extent of immune infiltration. CXCL13-producing Tfh cells and FDCs might catalyze the recruitment of other immune cells to the tumor, thereby initiating and/or enhancing TLS development and GC formation. The increased frequency of TLS and GC in conjunction with increased Tfh and Th1 gene expression in CD4+ TIL from extensively infiltrated BC, together with the combined activated/suppressed TIL profile, suggests that immune structures adjacent to the tumor bed may represent an important site for antitumor immune responses.

Figure 10
Organization of the immune infiltrate in extensively infiltrated breast tumors.

Clinical significance of CD4+ Tfh cells infiltrating tumors.

We tested this hypothesis by investigating the prognostic associations of Th gene expression profiles as a reflection of lymphocyte infiltration levels and/or a TLS presence in a given BC sample. We derived signatures by extracting the most significant and specific Tfh and Th1 genes from the Th subset gene profiles (Figure (Figure1,1, C and E) that were differentially expressed between extensively and minimally infiltrated tumors (detailed in Supplemental Table 7). We evaluated the association of these signatures with disease-free survival (DFS) in systemically untreated primary BC (n = 794 patients receiving no hormone or chemotherapy before or after surgery; Figure Figure11A)11A) and compared them with 2 published immune signatures (refs. 6, 8, and Supplemental Table 7). Our Tfh signature (8 genes) was consistently prognostic, demonstrating a linear association with survival in the whole population (P = 0.0036) as well as in the 3 main BC subtypes: HER2+ (P = 0.012), ER+/HER2 (P = 0.024), with borderline significance observed in ER/HER2 (P = 0.082). Given the importance of CXCL13 in Tfh and B cell recruitment, its prognostic associations as a single gene were also investigated, revealing a particularly strong association for the HER2+ subtype, as recently reported (38). The dominant prognostic value of CXCL13 within the Tfh signature is a reflection of its number one ranking in TIL gene expression changes detected in the extensive versus minimal comparison and our demonstration that Tfh cells are the principal producer cells in BC. This is in contrast to the Treg/activated T cell marker FOXP3, which as a single gene did not have any significant predictive value (Supplemental Table 7B). Our Th1 signature (12 genes) predicted survival in the HER2+ BC (P = 0.02) subtype, with the genes CXCL9 and IFNG providing similar results (Supplemental Table 7B).

Figure 11
An 8-gene Tfh signature strongly predicts positive clinical outcome in BC.

We next examined a BC cohort treated with preoperative chemotherapy (n = 996) (44), which is given up front prior to surgery with the pathological complete response (pCR) of the tumor (its disappearance at surgery) known to be associated with excellent long-term survival outcome. In this treatment setting, the Tfh and Th1 signatures, along with the CXCL13 single gene, were all strongly associated with a higher rate of pCR, particularly in the HER2+ subtype (Figure (Figure11B11B and Supplemental Table 7C). Together, these data support our hypothesis that the presence of CXCL13-producing Tfh cells may specify a TLS/GC presence in the tumor, with these structures producing antitumor immune responses associated with improved clinical responses.


The work presented in this study provides new insight into the composition and strategic location of the CD4+ T cell infiltrate and its association with clinical outcome in BC. We identified several aspects of the CD4+ T cell presence that we consider to be fundamentally important. First, while all Th subsets are present in the tumor they do not contribute equally, with more extensively infiltrated tumors distinguished by higher expression of Tfh, Th1, and T cell activation markers. Second, the mixture of activation and suppression observed in the CD4+ TIL (and S+SN–treated donor cells) suggests that their position and prevalence within the tumor dictates responsiveness, with extensively infiltrated tumors successfully sequestering higher concentrations of leukocytes in organized lymphoid structures (TLS). Third, despite tumor-mediated TCR/CD3 pathway suppression, the expression of some key immune transcription factors is consistently upregulated, and a restricted group of cytokines/chemokines are produced by the TIL. Fourth, BCs with extensive immune infiltrates are characterized by the presence of TLS, principally located adjacent to the tumor bed, which house the majority of CXCL13-producing Tfh cells and GC. Fifth, expression of an 8-gene Tfh signature that includes the CXCL13 gene was associated with a higher likelihood of response to preoperative chemotherapy and better DFS in systemically untreated patients with BC. Together, these data reveal that a detectable Tfh cell presence is associated with organized immune structures and long-term positive clinical outcome.

A recent quantitative evaluation of the leukocyte composition in breast tumors found that CD4+ and CD8+ TIL had an activated (CD27loCD69hiHLA-DRhiCCR4hiCCR5hi) memory (CD45RACCR7) phenotype (29). Our broad examination of surface markers in conjunction with gene expression profiling confirms and extends these findings by demonstrating that the CD4+ TIL are effector memory cells with all Th subpopulations represented. In contrast to most studies, we found that the CD4+ TIL produce a restricted repertoire of Th cytokines/chemokines, which are generally expressed at sub–T cell activation levels, particularly in minimally infiltrated tumors. The difference between our data and previous work could be attributed to our rapid isolation of CD4+ TIL without in vitro expansion, which provided insight into their in situ state, as well as our inclusion of minimally infiltrated tumors. Finally, eliminating enzymatic digestion, shown to alter TIL function and phenotype (45), also allowed us to retain SN from primary tumor homogenates for treatment of donor CD4+ T cells, which largely reproduced the TIL profiles in activated CD4+ T cells, further validating these data.

Curiously, this reduction in T cell activation and consequent low level cytokine/chemokine expression in the TIL is set against a background of upregulated REL and AP-1 superfamily transcription factors. REL (c-Rel) is a major player in the canonical NF-κB signaling pathway, integrating T cell activation signals and promoting Th1, Th17, and Treg responses (46). The conserved, homologous E3 ubiquitin ligase proteins, pellino 1 and 2, positively regulate NF-κB activation (47), with c-Rel shown to accumulate in T cells from mice deficient for PELI1 (48). While a specific function for pellino 2 in T cells has not been reported, it has been shown to regulate NF-κB–dependent IL-8 promoter activity (49). We detected a decrease in PELI2 in the TIL (Supplemental Table 2B), suggesting a potential mechanism for the observed upregulation of REL and IL8 gene expression.

AP-1/ATF factors also regulate important immune response genes, exemplified by their well-known cooperation with NFAT factors to induce cytokine gene expression (50). We detected upregulation of JUN, FOS (FOSB/FOSL2), and ATF3 in the TIL and SN+S–treated donor cells in parallel with a decrease in JUN, FOSB, and ATF3 in the rested TIL, suggesting that their expression is induced when activated cells enter the tumor microenvironment. A recent study has shown that AP-1 (FOS) is persistently upregulated in infiltrating T cells during tumor progression in mice (51). FOS upregulation specifically induces PD-1 expression on CD4 and CD8 TIL, which mediates their suppression upon contact with PD-L1–expressing tumor cells. While PD-L1 is not expressed on normal breast tissue, studies have shown that it is upregulated in breast tumors, particularly in high proliferative, ER BC (52). Disruption of AP-1–induced PD-1 expression on murine TIL was able to restore their cytokine expression (51), with potentially the same mechanism evoked for the reduced cytokine expression we detected in the global CD4+ TIL population. Based on current data, the role(s) PD-1 plays in regulating Tfh cells (a minority of the total CD4+ TIL) remains unclear. Murine studies have shown that PD-1+ Tfh cell interactions with PD-L1+/PD-L2+ B cells are important for regulating GC activities, with a deficiency in PD-L2 resulting in reduced Tfh IL-21 production and the generation of fewer plasma cells (53). The notion that PD-1 expression on Tfh cells elicits context-dependent responses in protected lymphoid structures is supported by a recent murine study showing that PD-1+ Tfh cells survive and function in gut-associated lymphoid follicles after anti–Thy-1 antibody treatment (54). PD-1 expression is often considered a sign of T cell exhaustion; however, our expanding knowledge indicates that it can also act as a signal for other functions, highlighted by the demonstration that CD8+ PD-1+ TIL produce higher levels of IFN-γ than PD-1 cells (55). Overall, current data suggests that, in contrast to effector T cell TIL, PD-1+ Tfh cells located in BC-associated TLS likely do not contact PD-L1+ tumor cells and are not directly affected by PD-1–mediated tumor suppression but are instead regulated by PD-1 to elicit other functions.

Studies of TIL have used various approaches to address the specific influence(s) exerted by individual Th subsets in the tumor microenvironment. Traditionally, Th1-mediated immunity has been considered as antitumoral, because patients whose tumors contain higher levels of Th1 cells are predicted to have longer DFS, while tumors associated with polarized Th2 and/or Treg subpopulation markers have a poorer prognosis (19). This view is complicated by the plasticity of Th differentiation (56), which involves shared surface receptors and cytokines that are often rapidly modulated in time and place, making it frequently difficult to clearly discriminate the type of response(s). Despite these limitations, a number of studies have shown that infiltrating T cell subsets can be used to gauge clinical outcome. The widely studied immune infiltrate in colorectal carcinoma has established that a higher density of intratumoral CD8+ and/or CD3+ memory cells is frequently associated with a better prognosis (57, 58). Tumor-associated Th1 cytokines, lead by IFN-γ, have consistently been linked with more potent antitumor immune responses in a variety of solid tumors (59, 60), with recent research showing that tumor-specific Th1 cells can effectively control tumor development (61, 62). Although IL-17 has been correlated with both protumor and antitumor immune responses (63), Th17 cells have been shown to synergize with IFN-γ to induce the important antitumor chemokines CXCL9 and CXCL10 (64), suggesting that the positive or negative Th17 activities reported may be context dependent. Presence of Foxp3+ Tregs in tumors is also inconsistent among tumor types, with their accumulation in some cancers associated with reduced patient survival, while in others they signal a better outcome. An important early study by Curiel et al. (65) found that tumor-associated Tregs were correlated with suppressed antitumor immunity and reduced survival in ovarian carcinoma. Foxp3 expression by tumor cells was shown to be an independent predictor of improved outcome in patients with HER2+ BC (66). A recent study of colorectal cancer has found that the presence of Foxp3+ tumor cells (Epcam+) but not Foxp3+ CD4+ T cells is indicative of a poor prognosis (67). In BC, the majority of studies investigating CD4+ TIL have been focused on Tregs (68), with their increased presence linked with a poor prognosis in ER+ disease (21, 69) but a good clinical outcome in ER disease (70). Further investigation is needed to more clearly define the roles played by individual Th subpopulations in different types of BC.

In this study, we have extended current knowledge of Th subsets infiltrating solid tumors by showing that, in addition to Th1 cells, a measurable Tfh presence is also significant and associated with better BC patient outcome. Tfh cells are relative newcomers to the Th subset family (71, 72) and have not been previously described in nonhematological tumors. While their role in antitumor immunity is unknown, studies of cellular interactions in secondary lymphoid organs show that Tfh cells are key players in the generation of T cell–dependent antibody responses and B cell memory (73). Collectively, these data (predominantly from animal models) demonstrate that these specialized Th cells are intimately involved in GC development and provide critical help for antigen-specific B cell maturation to high-affinity memory cells and long-lived plasma cells (28, 43, 74). While long considered minor players in antitumor immunity (75), plasma cells infiltrating non–small cell lung cancer (76) and CD20+ B cells infiltrating BC (77), ovarian cancer (78), melanoma (79), and colorectal carcinoma (80) have been associated with increased survival. Studies of B cells in BC have detected specific antibody responses to tumor antigens (81, 82) and correlated B cell gene expression signatures with better clinical outcome (9, 83). The data presented here show that the most important differences in the TIL profiles were related to the extent of infiltration, which identified important Th subset differences characterized by increased Th1 and particularly Tfh marker expression in extensively infiltrated tumors. We found that a detectable Tfh presence predicts longer survival in untreated patients as well as pCRs in preoperatively treated patients, which further suggests that B cell responses may constitute an important component of effective antitumor immunity in BC. Although the role(s) B cells play in cancer immunity is currently undefined, they could potentially affect antitumor immune responses via their antibody-producing capacities, APC functions, and/or production of specific cytokines and chemokines.

We found that a Tfh presence was principally associated with peritumoral TLS, which have been described primarily in the lung, in patients with chronic inflammatory diseases or as a reactive response to infection (84). These organized structures contain distinct T cell zones and B cell follicles with reactive GC similar to secondary lymphoid organs. Some earlier studies described lymphoid aggregates or organized lymphoid structures in tumors, including BC (81); however, their prognostic value has only recently been investigated in a study of non–small cell lung cancer, in which the number of mature DCs was used as an indicator for TLS (26), and in colorectal cancer, in which both lymphocyte aggregates (57) and active TLS, the latter identified by high chemokine expression levels (27), were associated with a better clinical outcome. While lymphoid structures containing FDCs or a high density of endothelial venules have been described in BC (81, 85) and other tumors, their immunological importance in these patients has not been specifically addressed. Our analysis of CD4+ T cell subsets in BC TLS found that elevated levels of CXCL13 expression were correlated with Tfh markers and the extent of tumor infiltration. These data led us to further demonstrate that CXCL13-producing Tfh cells signal the presence of organized TLS containing reactive GC that are associated with favorable clinical outcomes. Studies have shown that CXCL13 (in conjunction with CCL19, CCL21, TNF, and lymphotoxin) plays a critical role in the development and maintenance of secondary lymphoid organs (86) and is essential for dynamic GC formation in response to acute infection. Although CXCL13 has principally been defined as a stromal cell–produced (including FDCs) chemokine, PD-1hi Th cells were recently shown to be efficient CXCL13 producers (87). Our experiments used a variety of approaches to demonstrate that CD4+PD-1hiCD200hi Tfh cells infiltrating BC are a major source of CXCL13 production.

In BC, a high immune signal has been linked with better progression-free survival in overall patient groups as well as aggressive BC subtypes, including HER2+ (7, 8, 10), ER/HER2 (8, 10, 11), and highly proliferative tumors (9). The signals emanating from these analyses of total tumor tissue detect a broad spectrum of immune response genes, reflecting activities of the innate and adaptive immune responses, with some refined to a T cell metagene (10), B cell metagene (9), or signaling pathways (8). Additionally, two recent studies demonstrated that a higher immune score in the initial biopsy predicts increased pCR rates after preoperative chemotherapy (88), with the strongest association observed in the HER2+ and ER/HER2 subtypes (44). Generally, higher expression of an immune signature reflects a greater presence of immune cells, with the latter associated with a better prognosis. Our data confirm and extend these findings by demonstrating that a key positive prognostic element detected by these immune signatures is a Tfh presence in organized TLS, which may be a surrogate for effective responses to the tumor. A link between the patient’s natural ability to mount what appears to be a more comprehensive immune response in LN-like structures adjacent to the tumor bed and clinical outcome suggests that some patients might derive specific benefit from therapies designed to boost their immunity before the tumor, as a source of antigen, is removed.

The major findings in this study indicate that, despite the immune system’s failure to contain the growing tumor, the presence of CXCL13-producing Tfh cells is associated with organized immune structures adjacent to the tumor bed that potentially participate in propagating sustainable and effective long-term antitumor immunity. Leukocytes within the TLS could thus dynamically respond to evolving local tumor antigens, maintain activation, and generate long-lived memory cells while sequestered in a protected microenvironment. The mixture of activation and suppression that we observed in the CD4+ TIL may reflect the presence of functionally activated cells from the TLS combined with suppressed cells migrating through the intratumoral and peritumoral regions. Despite their imminent suppression once they move from the TLS, we suggest that some tumor-specific memory cells survive and maintain effective immunosurveillance that functions over the long-term to detect and eliminate residual tumor cells. Thus, patients whose immune systems mount an organized response to their tumors, specifically detectable by the Tfh signature, would be predicted to have a better response to preoperative chemotherapy or postsurgical DFS.


Patient population and clinical samples.

Tumor, LN, and/or blood samples were obtained from 70 untreated patients undergoing tumor resection for BC at the Jules Bordet Institute. Fresh tumor tissue, LN tissue, and PB from the 10 patients in the discovery set (P1–P10) and fresh tumor tissue from 60 patients in the confirmation set (TIL003–TIL132; and ipsilateral nonadjacent normal breast tissue when available) were analyzed. PB samples from 19 healthy female adults were used as controls for the discovery set (D1–D4) and the confirmation set (D5–D19). Clinicopathological patient data is detailed in Supplemental Table 1.

Tumor sample preparation.

Dissected tumor fragments from fresh surgical specimens were directly transferred into 3 ml X-VIVO 20 (Lonza) before 2 rapid rounds of mechanical dissociation with the GentleMACS Dissociator (Program A.01; Miltenyi Biotec). This approach yielded a >50% increase in cell viability compared with enzymatic digestion. The resulting cell suspension was filtered following each dissociator run using a 40-μm cell strainer (BD Falcon), washed with X-VIVO 20, centrifuged for 15 minutes at 600 g, and resuspended in X-VIVO 20 before isolation or flow cytometric analysis. The tumor SN was the initial 3 ml of X-VIVO 20 recovered after the first round of dissociation, which was subsequently clarified by centrifugation for 15 minutes at 13,000 g.

Cell isolation.

For molecular analyses, CD4+ T cells were positively purified from patient samples or healthy donor blood using Dynabeads CD4 (Invitrogen). Memory CD4+ T cells were purified by CD45RA depletion (Dynabeads M450 Epoxy [Invitrogen] coupled to an anti-CD45RA antibody [304102; Biolegend]) prior to CD4+ selection. Additional tumor cell populations were purified using Dynabeads M-450 Epoxy coupled with monoclonal antibodies to CD14, CD45, or EpCAM (301801, 304001, and 324201; Biolegend). For primary cells treated with tumor SN, total CD4+ or memory (CD45RA = RO+) CD4+ cells were negatively purified using the CD4+ T cell Isolation Kit II or Memory CD4+ T cell Isolation Kit (Miltenyi Biotec). The cell purification protocols were controlled by flow cytometry with negatively purified samples >98% pure and positively isolated CD4+ TIL >95% pure.

Treatment with tumor SN.

Total CD4+ or memory CD4+ cells (2 × 106 cells/ml) purified from healthy donor blood were incubated in X-VIVO 20 overnight following isolation. Cell viability was controlled the following day by flow cytometry (>95%), and then an equal volume of tumor SN or X-VIVO 20 was added with or without anti-CD3 (317304, clone OKT3; Biolegend) and anti-CD28 (555725, clone CD28.2; BD Pharmingen), each at 1 μg/ml final concentration. The cells were recovered 24 hours after treatment for analysis using microarrays, qRT-PCR (including a kinetic experiment for IFNG and IL2 gene expression over 48 hours after treatment; Supplemental Table 5H), and/or flow cytometry.


10 ng (discovery set) or 100 ng (confirmation set) high-quality total RNA was labeled following the manufacturer’s protocols for probe preparation and hybridization on the Affymetrix U133 Plus 2.0 GeneChip. The gene expression array data has been deposited into the Gene Expression Omnibus under accession number (GSE36769).

Flow cytometry.

Samples assessed for the expression of 60 cell surface markers (duplicates or triplicates were assessed for each marker) were incubated individually or in combinations of antibodies (listed in Supplemental Figures 1–3) for 45 minutes at 4°C in 50 μl X-VIVO 20 followed by washing with 2 ml PBS and immediate analysis on a FACSCalibur (BD Biosciences) without fixation. The Cytofix/Cytoperm Kit (BD Biosciences) was used for intracellular staining with anti-CXCL13 (IC801A; R&D Systems).


RNA was extracted using TRIzol Reagent (Invitrogen) and reverse transcribed into cDNA using the High-Capacity RNA-to-cDNA Kit (Applied Biosystems) following standard procedures. Real-time PCR reactions were performed using commercially available Gene Expression Assays (Applied Biosystems or Qiagen) or published primers (detailed in Supplemental Table 5A) and iTaq SYBR Green Supermix With ROX (Bio-Rad) on an ABI 7900HT Prism sequence detector (Applied Biosystems).


Four-μm sections of paraffin-embedded tumor blocks from P1–P10 were labeled with anti-CD4 and anti-CD3 antibodies. Successive sections from 15 patients from the confirmation set were labeled with the top 9 antibodies listed in Supplemental Figure 4 using the Endogenous Biotin Blocking Kit (Ventana) and iVIEW DAB Detection Kit (Ventana) on a BenchMark XT IHC/ISH slide stainer (Ventana). For CXCL13 labeling, mounted sections were deparaffinized with xylene, pretreated with citrate 10 mM, pH 6.0, at 95°C to 99°C for 20 minutes, exposed to a 3% hydrogen peroxide solution to quench endogenous peroxidase activity, and blocked with rabbit serum (Sigma-Aldrich) for 1 hour prior to incubation with a purified goat anti-human polyclonal antibody to CXCL13 (1:100, AF801; R&D Systems) in a moist chamber at 4°C overnight. For each tumor, one section was treated in parallel without the primary antibody as a negative control. Subsequent incubations were carried out with a biotinylated rabbit anti-goat secondary antibody (Vector Laboratories) for 30 minutes at room temperature, followed by the HRP streptavidin reagent (Zymed) and the DAB + Substrate Chromogen System (Dako). The slides were counterstained with hematoxylin (Sigma-Aldrich) and mounted on a Tissue-Tek Prisma Automated Slide Stainer (Sakura).

Survival analysis.

The Th1 and Tfh gene signatures derived in this study along with previously published immune gene signatures were assessed for their power to predict either 10-year DFS or pCR after neoadjuvant chemotherapy. DFS analyses were performed using 794 systemically untreated patients with BC from 8 public microarray data sets (Supplemental Table 7F). The signature scores (signed average of expression values for the genes in the signature) were computed as in Desmedt et al. (8). Three categories of gene expression cut-off values (high, intermediate, and low) were defined using tertiles of the continuous signature scores. In these data sets, BC subtypes were defined using a 2-gene classification based on ESR1 (also known as ER) and ERBB2 (also known as HER2) gene expression (89). pCR analyses were performed using 966 patients treated with neoadjuvant chemotherapy from 8 published studies, as in Ignatiadis et al. (44). BC subtypes were defined on the basis of ER protein expression by IHC and HER2 amplification by IHC and fluorescent in situ hybridization in the original publications. When unavailable, ER and HER2 status was assigned according to bimodal normalized ESR1 and ERBB2 gene expression (44). The association between an individual gene signature and pCR was based on an estimated odds ratios and 95% CI (44).


P values for nonmicroarray data were generated using a 2-tailed Student’s t test with unequal variance (or a χ2 test where indicated). A P value of less than 0.05 was considered as significant. Individual patient microarray data, our experimental data, and publicly available data for individual Th subsets were differentially analyzed based on the type and number of samples in the set by using the specifically adapted methods and criteria detailed in Supplemental Methods.

Study approval.

All primary breast tissue, LN, and blood samples used in this study were taken from individuals treated at the Institute Jules Bordet. All patients signed a protocol-specific consent. Healthy donor blood samples were taken from volunteers who signed an informed consent. The protocols used for human studies were approved by the Medical Ethics Committee of the Institut Jules Bordet.

Supplementary Material

Supplemental data:
Supplemental Excel file 1:
Click here to view.(1017K, xlsx)
Supplemental Excel file 2:
Supplemental Excel file 3:
Supplemental Excel file 4:
Supplemental Excel file 5:
Supplemental Excel file 6:
Supplemental Excel file 7:


We thank Nicolas Sirtaine for advice in reading the H&E slides, Samira Majjaj for technical advice on the gene chip hybridizations, and Anne Zerghe and Ghizlane Rouas for expert technical assistance in establishing the tumor homogenate protocols and CXCL13 IHC experiments, respectively. This work was supported by grants from the Belgian Fund for Scientific Research (FNRS), Les Amis de l’Institut Bordet, FNRS-Opération Télévie, Plan Cancer of Belgium, Fonds Lambeau-Marteaux, and Fonds Barsy. C. Gu-Trantien is a fellow and S. Garaud is a postdoc at the FNRS-Télévie, and C. Sotiriou is a research director at the FRS-FNRS.


Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article:J Clin Invest. 2013;123(7):2873–2892. doi:10.1172/JCI67428.

Sherene Loi’s present address is: Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.

Marie Ravoet’s present address is: Centre de Génétique Humaine, Cliniques Universitaires St. Luc-UCL, Bruxelles, Belgium.

Benjamin Haibe-Kains’s present address is: Bioinformatics and Computational Genomics Laboratory, Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada.

Stefan Michiels’s present address is: Service de Biostatistique et d’Epidémiologie, Institut Gustave-Roussy, Villejuif, France.


1. Perou CM, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. doi: 10.1038/35021093. [PubMed] [Cross Ref]
2. Sorlie T, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–10874. doi: 10.1073/pnas.191367098. [PubMed] [Cross Ref]
3. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360(8):790–800. doi: 10.1056/NEJMra0801289. [PubMed] [Cross Ref]
4. Sotiriou C, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006;98(4):262–272. doi: 10.1093/jnci/djj052. [PubMed] [Cross Ref]
5. Ascierto ML, et al. An immunologic portrait of cancer. J Transl Med. 2011;9:146. doi: 10.1186/1479-5876-9-146. [PMC free article] [PubMed] [Cross Ref]
6. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol. 2007;8(8):R157. doi: 10.1186/gb-2007-8-8-r157. [PMC free article] [PubMed] [Cross Ref]
7. Alexe G, et al. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res. 2007;67(22):10669–10676. doi: 10.1158/0008-5472.CAN-07-0539. [PubMed] [Cross Ref]
8. Desmedt C, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008;14(16):5158–5165. doi: 10.1158/1078-0432.CCR-07-4756. [PubMed] [Cross Ref]
9. Schmidt M, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008;68(13):5405–5413. doi: 10.1158/0008-5472.CAN-07-5206. [PubMed] [Cross Ref]
10. Rody A, et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res. 2009;11(2):R15. doi: 10.1186/bcr2234. [PMC free article] [PubMed] [Cross Ref]
11. Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res. 2010;12(5):R85. doi: 10.1186/bcr2753. [PMC free article] [PubMed] [Cross Ref]
12. Ascierto ML, et al. A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat. 2012;131(3):871–880. doi: 10.1007/s10549-011-1470-x. [PMC free article] [PubMed] [Cross Ref]
13. Rody A, et al. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res. 2011;13(5):R97. doi: 10.1186/bcr3035. [PMC free article] [PubMed] [Cross Ref]
14. Rahir G, Moser M. Tumor microenvironment and lymphocyte infiltration. Cancer Immunol Immunother. 2012;61(6):751–759. doi: 10.1007/s00262-012-1253-1. [PubMed] [Cross Ref]
15. Mahmoud SM, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949–1955. doi: 10.1200/JCO.2010.30.5037. [PubMed] [Cross Ref]
16. Mahmoud S, Lee A, Ellis I, Green A. CD8(+) T lymphocytes infiltrating breast cancer: A promising new prognostic marker? Oncoimmunology. 2012;1(3):364–365. [PMC free article] [PubMed]
17. Bos R, Marquardt KL, Cheung J, Sherman LA. Functional differences between low- and high-affinity CD8(+) T cells in the tumor environment. Oncoimmunology. 2012;1(8):1239–1247. doi: 10.4161/onci.21285. [PMC free article] [PubMed] [Cross Ref]
18. Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 2010;70(21):8368–8377. doi: 10.1158/0008-5472.CAN-10-1322. [PMC free article] [PubMed] [Cross Ref]
19. Ruffell B, DeNardo DG, Affara NI, Coussens LM. Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev. 2010;21(1):3–10. doi: 10.1016/j.cytogfr.2009.11.002. [PMC free article] [PubMed] [Cross Ref]
20. Zamarron BF, Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 2011;7(5):651–658. [PMC free article] [PubMed]
21. Gobert M, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009;69(5):2000–2009. doi: 10.1158/0008-5472.CAN-08-2360. [PubMed] [Cross Ref]
22. Wilke CM, et al. Th17 cells in cancer: help or hindrance? Carcinogenesis. 2011;32(5):643–649. doi: 10.1093/carcin/bgr019. [PMC free article] [PubMed] [Cross Ref]
23. Ye J, Livergood RS, Peng G. The role and regulation of human Th17 cells in tumor immunity. Am J Pathol. 2013;182(1):10–20. doi: 10.1016/j.ajpath.2012.08.041. [PubMed] [Cross Ref]
24. deLeeuw RJ, Kost SE, Kakal JA, Nelson BH. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res. 2012;18(11):3022–3029. doi: 10.1158/1078-0432.CCR-11-3216. [PubMed] [Cross Ref]
25. de Chaisemartin L, et al. Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res. 2011;71(20):6391–6399. doi: 10.1158/0008-5472.CAN-11-0952. [PubMed] [Cross Ref]
26. Dieu-Nosjean MC, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008;26(27):4410–4417. doi: 10.1200/JCO.2007.15.0284. [PubMed] [Cross Ref]
27. Coppola D, et al. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am J Pathol. 2011;179(1):37–45. doi: 10.1016/j.ajpath.2011.03.007. [PubMed] [Cross Ref]
28. Vinuesa CG, Cyster JG. How T cells earn the follicular rite of passage. Immunity. 2011;35(5):671–680. doi: 10.1016/j.immuni.2011.11.001. [PubMed] [Cross Ref]
29. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A. 2012;109(8):2796–2801. doi: 10.1073/pnas.1104303108. [PubMed] [Cross Ref]
30. Chtanova T, et al. Identification of T cell-restricted genes, and signatures for different T cell responses, using a comprehensive collection of microarray datasets. J Immunol. 2005;175(12):7837–7847. [PubMed]
31. Miyara M, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;30(6):899–911. doi: 10.1016/j.immuni.2009.03.019. [PubMed] [Cross Ref]
32. Lee MS, Hanspers K, Barker CS, Korn AP, McCune JM. Gene expression profiles during human CD4+ T cell differentiation. Int Immunol. 2004;16(8):1109–1124. doi: 10.1093/intimm/dxh112. [PubMed] [Cross Ref]
33. Ravoet M, et al. Molecular profiling of CD3-CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways. Blood. 2009;114(14):2969–2983. doi: 10.1182/blood-2008-08-175091. [PubMed] [Cross Ref]
34. Zaunders JJ, et al. Early proliferation of CCR5(+) CD38(+++) antigen-specific CD4(+) Th1 effector cells during primary HIV-1 infection. Blood. 2005;106(5):1660–1667. doi: 10.1182/blood-2005-01-0206. [PubMed] [Cross Ref]
35. Baniyash M. TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol. 2004;4(9):675–687. [PubMed]
36. Fazilleau N, Mark L, McHeyzer-Williams LJ, McHeyzer-Williams MG. Follicular helper T cells: lineage and location. Immunity. 2009;30(3):324–335. doi: 10.1016/j.immuni.2009.03.003. [PMC free article] [PubMed] [Cross Ref]
37. Balkwill FR. The chemokine system and cancer. J Pathol. 2012;226(2):148–157. doi: 10.1002/path.3029. [PubMed] [Cross Ref]
38. Razis E, et al. Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression. Clin Breast Cancer. 2012;12(3):183–193. doi: 10.1016/j.clbc.2012.03.006. [PubMed] [Cross Ref]
39. Panse J, et al. Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. Br J Cancer. 2008;99(6):930–938. doi: 10.1038/sj.bjc.6604621. [PMC free article] [PubMed] [Cross Ref]
40. Link A, et al. Association of T-zone reticular networks and conduits with ectopic lymphoid tissues in mice and humans. Am J Pathol. 2011;178(4):1662–1675. doi: 10.1016/j.ajpath.2010.12.039. [PMC free article] [PubMed] [Cross Ref]
41. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol. 2011;29:621–663. doi: 10.1146/annurev-immunol-031210-101400. [PubMed] [Cross Ref]
42. Viegas MS, et al. CD38 plays a role in effective containment of mycobacteria within granulomata and polarization of Th1 immune responses against Mycobacterium avium. Microbes Infect. 2007;9(7):847–854. doi: 10.1016/j.micinf.2007.03.003. [PubMed] [Cross Ref]
43. Crotty S. The 1-1-1 fallacy. Immunol Rev. 2012;247(1):133–142. doi: 10.1111/j.1600-065X.2012.01117.x. [PubMed] [Cross Ref]
44. Ignatiadis M, et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol. 2012;30(16):1996–2004. doi: 10.1200/JCO.2011.39.5624. [PubMed] [Cross Ref]
45. Grange C, et al. Phenotypic characterization and functional analysis of human tumor immune infiltration after mechanical and enzymatic disaggregation. J Immunol Methods. 2011;372(1–2):119–126. doi: 10.1016/j.jim.2011.07.002. [PubMed] [Cross Ref]
46. Hayden MS, Ghosh S. NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012;26(3):203–234. doi: 10.1101/gad.183434.111. [PubMed] [Cross Ref]
47. Kim TW, et al. Pellino 2 is critical for Toll-like receptor/interleukin-1 receptor (TLR/IL-1R)-mediated post-transcriptional control. J Biol Chem. 2012;287(30):25686–25695. doi: 10.1074/jbc.M112.352625. [PMC free article] [PubMed] [Cross Ref]
48. Chang M, et al. The ubiquitin ligase Peli1 negatively regulates T cell activation and prevents autoimmunity. Nat Immunol. 2011;12(10):1002–1009. doi: 10.1038/ni.2090. [PMC free article] [PubMed] [Cross Ref]
49. Yu KY, Kwon HJ, Norman DA, Vig E, Goebl MG, Harrington MA. Cutting edge: mouse pellino-2 modulates IL-1 and lipopolysaccharide signaling. J Immunol. 2002;169(8):4075–4078. [PubMed]
50. Macian F, Lopez-Rodriguez C, Rao A. Partners in transcription: NFAT and AP-1. Oncogene. 2001;20(19):2476–2489. doi: 10.1038/sj.onc.1204386. [PubMed] [Cross Ref]
51. Xiao G, Deng A, Liu H, Ge G, Liu X. Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1. Proc Natl Acad Sci U S A. 2012;109(38):15419–15424. doi: 10.1073/pnas.1206370109. [PubMed] [Cross Ref]
52. Ghebeh H, et al. Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer. 2007;121(4):751–758. doi: 10.1002/ijc.22703. [PubMed] [Cross Ref]
53. Good-Jacobson KL, Szumilas CG, Chen L, Sharpe AH, Tomayko MM, Shlomchik MJ. PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat Immunol. 2010;11(6):535–542. doi: 10.1038/ni.1877. [PMC free article] [PubMed] [Cross Ref]
54. Mihalj M, Kellermayer Z, Balogh P. Int Immunol. Follicles in gut-associated lymphoid tissues create preferential survival niches for follicular Th cells escaping Thy-1-specific depletion in mice [published online ahead of print February 28, 2013]. doi: 10.1093/intimm/dxt001 . [PubMed] [Cross Ref]
55. Inozume T, et al. Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. J Immunother. 2010;33(9):956–964. doi: 10.1097/CJI.0b013e3181fad2b0. [PMC free article] [PubMed] [Cross Ref]
56. O’Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science. 2010;327(5969):1098–1102. doi: 10.1126/science.1178334. [PMC free article] [PubMed] [Cross Ref]
57. Galon J, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–1964. doi: 10.1126/science.1129139. [PubMed] [Cross Ref]
58. Yoon HH, Orrock JM, Foster NR, Sargent DJ, Smyrk TC, Sinicrope FA. Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas. PloS One. 2012;7(8):e42274. doi: 10.1371/journal.pone.0042274. [PMC free article] [PubMed] [Cross Ref]
59. Shankaran V, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410(6832):1107–1111. doi: 10.1038/35074122. [PubMed] [Cross Ref]
60. Curtis NJ, Primrose JN, Thomas GJ, Mirnezami AH, Ottensmeier CH. The adaptive immune response to colorectal cancer: from the laboratory to clinical practice. Eur J Surg Oncol. 2012;38(10):889–896. doi: 10.1016/j.ejso.2012.05.011. [PubMed] [Cross Ref]
61. Haabeth OA, et al. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun. 2011;2:240. doi: 10.1038/ncomms1239. [PMC free article] [PubMed] [Cross Ref]
62. Braumuller H, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature. 2013;494(7437):361–365. doi: 10.1038/nature11824. [PubMed] [Cross Ref]
63. Ji Y, Zhang W. Th17 cells: positive or negative role in tumor? Cancer Immunol Immunother. 2010;59(7):979–987. doi: 10.1007/s00262-010-0849-6. [PubMed] [Cross Ref]
64. Kryczek I, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009;114(6):1141–1149. doi: 10.1182/blood-2009-03-208249. [PubMed] [Cross Ref]
65. Curiel TJ, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942–949. doi: 10.1038/nm1093. [PubMed] [Cross Ref]
66. Ladoire S, et al. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2011;125(1):65–72. doi: 10.1007/s10549-010-0831-1. [PubMed] [Cross Ref]
67. Kim M, et al. Expression of foxp3 in colorectal cancer but not in treg cells correlates with disease progression in patients with colorectal cancer. PloS One. 2013;8(1):e53630. doi: 10.1371/journal.pone.0053630. [PMC free article] [PubMed] [Cross Ref]
68. Watanabe MA, Oda JM, Amarante MK, Cesar Voltarelli J. Regulatory T cells and breast cancer: implications for immunopathogenesis. Cancer Metastasis Rev. 2010;29(4):569–579. doi: 10.1007/s10555-010-9247-y. [PubMed] [Cross Ref]
69. Bates GJ, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006;24(34):5373–5380. doi: 10.1200/JCO.2006.05.9584. [PubMed] [Cross Ref]
70. West NR, et al. Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer. 2013;108(1):155–162. doi: 10.1038/bjc.2012.524. [PMC free article] [PubMed] [Cross Ref]
71. Breitfeld D, et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med. 2000;192(11):1545–1552. doi: 10.1084/jem.192.11.1545. [PMC free article] [PubMed] [Cross Ref]
72. Schaerli P, Willimann K, Lang AB, Lipp M, Loetscher P, Moser B. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med. 2000;192(11):1553–1562. doi: 10.1084/jem.192.11.1553. [PMC free article] [PubMed] [Cross Ref]
73. McHeyzer-Williams M, Okitsu S, Wang N, McHeyzer-Williams L. Molecular programming of B cell memory. Nat Rev Immunol. 2012;12(1):24–34. [PMC free article] [PubMed]
74. Ramiscal RR, Vinuesa CG. T-cell subsets in the germinal center. Immunol Rev. 2013;252(1):146–155. doi: 10.1111/imr.12031. [PubMed] [Cross Ref]
75. Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol. 2010;185(9):4977–4982. doi: 10.4049/jimmunol.1001323. [PubMed] [Cross Ref]
76. Lohr M, et al. The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. Cancer Lett. 2013;333(2):222–228. doi: 10.1016/j.canlet.2013.01.036. [PubMed] [Cross Ref]
77. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat. 2012;132(2):545–553. doi: 10.1007/s10549-011-1620-1. [PubMed] [Cross Ref]
78. Nielsen JS, et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res. 2012;18(12):3281–3292. doi: 10.1158/1078-0432.CCR-12-0234. [PubMed] [Cross Ref]
79. Ladanyi A, et al. Prognostic impact of B-cell density in cutaneous melanoma. Cancer Immunol Immunother. 2011;60(12):1729–1738. doi: 10.1007/s00262-011-1071-x. [PubMed] [Cross Ref]
80. Maletzki C, Jahnke A, Ostwald C, Klar E, Prall F, Linnebacher M. Ex-vivo clonally expanded B lymphocytes infiltrating colorectal carcinoma are of mature immunophenotype and produce functional IgG. PLoS One. 2012;7(2):e32639. doi: 10.1371/journal.pone.0032639. [PMC free article] [PubMed] [Cross Ref]
81. Coronella JA, et al. Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol. 2002;169(4):1829–1836. [PubMed]
82. Coronella-Wood JA, Hersh EM. Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother. 2003;52(12):715–738. doi: 10.1007/s00262-003-0409-4. [PubMed] [Cross Ref]
83. Bianchini G, et al. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol. 2010;28(28):4316–4323. doi: 10.1200/JCO.2009.27.2419. [PubMed] [Cross Ref]
84. Foo SY, Phipps S. Regulation of inducible BALT formation and contribution to immunity and pathology. Mucosal Immunol. 2010;3(6):537–544. doi: 10.1038/mi.2010.52. [PubMed] [Cross Ref]
85. Martinet L, et al. Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res. 2011;71(17):5678–5687. doi: 10.1158/0008-5472.CAN-11-0431. [PubMed] [Cross Ref]
86. Muller G, Hopken UE, Lipp M. The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity. Immunol Rev. 2003;195:117–135. doi: 10.1034/j.1600-065X.2003.00073.x. [PubMed] [Cross Ref]
87. Wang C, Hillsamer P, Kim CH. Phenotype, effector function, and tissue localization of PD-1-expressing human follicular helper T cell subsets. BMC Immunol. 2011;12:53. doi: 10.1186/1471-2172-12-53. [PMC free article] [PubMed] [Cross Ref]
88. Denkert C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105–113. doi: 10.1200/JCO.2009.23.7370. [PubMed] [Cross Ref]
89. Haibe-Kains B, et al. A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst. 2012;104(4):311–325. doi: 10.1093/jnci/djr545. [PMC free article] [PubMed] [Cross Ref]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation